UBS Strongly Resets Lilly Stock Target The pharmaceutical giant Eli Lilly has been riding high lately, with analysts scrambling to raise their price targets for the company's shares.
The latest move by UBS setting a $1,425 target is just the latest example of this trend. However, beneath the surface, warning signs are emerging that the bull run may be coming to an end.
Lilly's growth has been driven in part by its diabetes and obesity treatments, Mounjaro and Zepbound. These drugs have seen impressive revenue increases: $8.